Originally published by our sister publication Pain Medicine News
By Myles Starr
The preemptive use of levetiracetam (LEV), in conjunction with opioids, as an analgesic is supported by findings of a recent study.
The double-blind, randomized, placebo-controlled study included 42 participants (18-60 years of age; 22 men and 20 women) divided into a control or LEV group (Cureus 2023;15[1]:e33281). Patients with a history of substance abuse, hypersensitivity to LEV, or “significant respiratory,